1 July 2022 - The July 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
22 June 2022 - Approval based on the Phase II GEOMETRY mono-1 trial, which showed an overall response rate of 51.6% ...
22 June 2022 - This approval is supported by 98.4 per cent cure rate across this group of patients who ...
22 June 2022 - Approval supported by results from Phase II ROAR and NCI-MATCH studies demonstrating overall response rates up to ...
22 June 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC on ...
22 June 2022 - The Australian Government today launched an $11 million six-week campaign to encourage people to get vaccinated for ...
21 June 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using slow-release ...
22 June 2022 - Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four ...
22 June 2022 - Krystal Biotech announced today the submission of a biologics license application to the U.S. FDA seeking ...
22 June 2022 - Ikena Oncology today announced that the U.S. FDA has granted fast track designation for IK-930, the Company’s ...
21 June 2022 - No lower age restriction for treatment. ...
22 June 2022 - A British startup that uses virtual reality to help deliver cognitive behaviour therapy has been granted a ...
22 June 2022 - Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan demonstrated superior progression-free and ...
21 June 2022 - Phase 2b study in MAB pulmonary infections on-going and enrolling as planned. ...
14 June 2022 - Application is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR ...
22 June 2022 - Medicare’s drug program could have saved up to $3.6 billion in 2020 by mirroring the pricing ...